Skip to main content
. 2007 Jul 18;2007(3):CD006063. doi: 10.1002/14651858.CD006063.pub2
Characteristic Quality of life Costs HbA1c [%] (SD) Notes
Derosa 2004 
 
 I1: rosiglitazone 4 mg + glimepiride 4 mg 
 C1: pioglitazone 15 mg + glimepiride 4 mg not investigated not investigated I1: 
 end of study data: 6.7 (0.9) 
 change data: 
 C1: 
 end of study data: 6.8 (0.8) 
 change data: ./.
Derosa 2006a 
 
 I1: rosiglitazone 4 mg + metformin 3 g 
 C1: pioglitazone 15 mg + metformin 3 g not investigated not investigated I1: 
 end of study data: 6.8 (0.5) 
 change data: ‐1.3 
 C1: 
 end of study data: 6.8 (0.3) 
 change data: ‐1.4 change data calculated
Derosa 2006b 
 
 I1: rosiglitazone 4 mg + metformin 1.5 g 
 C1: glimepiride 2 mg + metformin 1.5 g not investigated not investigated I1: 
 end of study data: 6.8 (0.6) 
 change data: 
 C1: 
 end of study data: 7.0 (0.7) 
 change data: ./.
Garber 2006 
 
 I1: rosiglitazone 4 mg + metformin 2 g 
 C1: glibenclamide 5 mg + metformin 1 g not investigated not investigated I1: 
 end of study data: 
 change data: ‐1.1 
 C1: 
 end of study data: 
 change data: ‐1.5 "change data" from abstract
Goldberg 2005 
 
 I1: rosiglitazone 8 mg 
 C1: pioglitazone 45 mg not investigated not investigated I1: 
 end of study data: 
 change data: ‐0.6 (1.89) 
 C1: 
 end of study data: 
 change data: ‐0.7 (1.91) SDs calculated
Hanefeld 2007 
 I1: rosiglitazone (2 mg bid) + placebo 
 I2: rosiglitazone (4 mg bid) + placebo 
 C1: glibenclamide up to 15 mg + placebo not investigated not investigated I1: 
 end of study data: 
 change data: ‐0.3 
 I2: 
 end of study data: 
 change data: ‐0.5 
 I1: 
 end of study data: 
 change data: ‐0.7 ./.
Hällsten 2002 
 
 I1: rosiglitazone 8 mg 
 I2: metformin 2 g 
 C1: placebo not investigated not investigated I1: 
 end of study data: 6.5 (0.75) 
 change data: 
 I2: 
 end of study data: 6.2 (0.72) 
 change data: 
 C1: 
 end of study data: 6.1 (0.37) 
 change data: SDs calculated
Jung 2005 I1: rosiglitazone 4 mg + glimepiride 4 mg C1: metformin 1 g + glimepiride 4 mg not investigated not investigated I1: 
 end of study data: 7.8 (1.1) 
 change data: 
 C1: 
 end of study data: 8.0 (1.1) 
 change data: ./.
Kahn 2006 
 
 I1: rosiglitazone max. 8 mg 
 C1: metformin max. 2 g 
 C2: glyburide max. 15 mg not yet reported but mentioned in the publication of the study design (Diabetes Care 2002) not yet reported but mentioned in the publication of the study design (Diabetes Care 2002) I1: 
 end of study data: 7.1 
 change data: 
 C1: 
 end of study data: 7.3 
 change data: 
 C2: 
 end of study data: 7.4 
 change data: estimated from graph (four year data)
Ko 2006 
 
 I1: rosiglitazone max. 8 mg 
 + (sulfonylurea +/‐ metformin) 
 C1: "bedtime insulin" 
 + (sulfonylurea +/‐ metformin) not investigated not investigated I1: 
 end of study data: 9.1 (2.0) 
 change data: ‐1.1 (1.7) 
 C1: 
 end of study data: 8.3 (1.3) 
 change data: ‐1.3 (1.6) ./.
Lebovitz 2001 
 
 I1: rosiglitazone 4 mg 
 I2: rosiglitazone 8 mg 
 C1: placebo not investigated not investigated I1: 
 end of study data: 
 change data: ‐0.3 
 I2: 
 end of study data 
 change data: ‐0.6 
 C1: 
 end of study data: 
 change data: +0.9 ./.
Ovalle 2004 
 
 I1: rosiglitazone 8 mg 
 C1: insulin (premixed 70/30) not investigated not investigated I1: 
 end of study data: 7.8 (0.5) 
 change data: 
 C1: 
 end of study data: 7.8 (0.3) 
 change data: ./.
Philipps 2001 
 
 I1: rosiglitazone 
 4 mg o.d.; 2 mg b.i.d.; 8 mg o.d.; 4 mg b.i.d. 
 C1: placebo not investigated not investigated patients who had received prior oral monotherapy: 
 I1: 
 end of study data: 
 change data: 4 mg o.d. (+0.14); 2 mg b.i.d. (+0.02); 8 mg o.d. (‐0.26); 4 mg b.i.d. (‐0.54) 
 C1: 
 end of study data: 
 change data: +0.98 SDs calculated
Raskin 2004 
 
 I1: rosiglitazone 8 mg 
 I2: repaglinide 12 mg 
 C1: repaglinide + rosiglitazone 6 mg / 4 mg not investigated not investigated I1: 
 end of study data: 8.5 
 change data: ‐0.56 (1.0) 
 I2: 
 end of study data: 9.1 
 change data: ‐0.17 (1.1) 
 C2: 
 end of study data: 7.7 
 change data: ‐1.43 (1.1) SDs calculated
Rosenstock 2006b 
 
 I1: rosiglitazone 8 mg + metformin 2g + sulfonylurea 
 C1: insulin glargine 10 units/day + metformin 2g + sulfonylurea not investigated I1: $ 1,603 
 C1: $ 1,368 I1: 
 end of study data: 
 change data: ‐1.51 
 C1: 
 end of study data: 
 change data: ‐1.66 ./.
Stocker 2007 
 
 I1: rosiglitazone 4 mg 
 C1: metformin 1.7 g not investigated not investigated I1: 
 end of study data: 
 change data: ‐1.08 (0.14) 
 C1: 
 end of study data: 
 change data: ‐1.19 (0.13) (SE or SD)?
Sutton 2002 
 
 I1: rosiglitazone 8 mg 
 C1: glyburide (mean 10.5 mg) not investigated not investigated I1: 
 end of study data: 8.1 (0.3) 
 change data: 
 C1: 
 end of study data: 8.4 (0.2) 
 change data: ./.
Yang 2002 
 
 I1: rosiglitazone 4 mg 
 C1: placebo not investigated not investigated I1: 
 end of study data: 
 change data: ‐0.7 (1.04) 
 C1: 
 end of study data: 
 change data: 0.4 (1.3) ./.
         
Footnotes
? = unclear; I = intervention; C = control; o.d. = once daily; b.i.d. = twice daily